Q-omics provides the consensus-scored MARCHF6 profile across patient tissues and cancer cell-line models. MARCHF6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MARCHF6 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, MARCHF6 RNA expression shows 21,010 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where MARCHF6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARCHF6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARCHF6 survival associations across molecular data types. MARCHF6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARCHF6 RNA expression–survival associations across cancer types. High MARCHF6 expression shows unfavorable associations in KIRP, ACC and UVM, but favorable associations in KIRC, HNSC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MARCHF6 RNA expression.
This table summarizes MARCHF6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MARCHF6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARCHF6 shows higher tumor expression in HNSC, LIHC, LUAD, KIRC, LUSC and STAD. The HNSC box plot shows higher MARCHF6 RNA expression in tumor versus normal tissue (log2 FC = +0.915, t-test p < 0.001).
This table shows molecular features associated with MARCHF6 in patient tissues and cancer cell lines. In patient samples, MARCHF6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MARCHF6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
